[go: up one dir, main page]

WO1999065938A2 - Fy7 polymerase - Google Patents

Fy7 polymerase Download PDF

Info

Publication number
WO1999065938A2
WO1999065938A2 PCT/US1999/013741 US9913741W WO9965938A2 WO 1999065938 A2 WO1999065938 A2 WO 1999065938A2 US 9913741 W US9913741 W US 9913741W WO 9965938 A2 WO9965938 A2 WO 9965938A2
Authority
WO
WIPO (PCT)
Prior art keywords
dna
dna polymerase
polymerase
recombinant
sequencing
Prior art date
Application number
PCT/US1999/013741
Other languages
English (en)
Other versions
WO1999065938A3 (fr
WO1999065938A9 (fr
Inventor
Maria Davis
Carl W. Fuller
Joseph A. Mamone
Lin Huang
Original Assignee
Amersham Pharmacia Biotech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Pharmacia Biotech Inc. filed Critical Amersham Pharmacia Biotech Inc.
Priority to AU45757/99A priority Critical patent/AU768993B2/en
Priority to DE69936919T priority patent/DE69936919T2/de
Priority to JP2000554763A priority patent/JP4349545B2/ja
Priority to CA2330735A priority patent/CA2330735C/fr
Priority to EP99928766A priority patent/EP1086209B1/fr
Publication of WO1999065938A2 publication Critical patent/WO1999065938A2/fr
Publication of WO1999065938A3 publication Critical patent/WO1999065938A3/fr
Publication of WO1999065938A9 publication Critical patent/WO1999065938A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase

Definitions

  • the instant disclosure pertains to thermostable DNA polymerases which exhibit improved robustness and efficiency.
  • DNA polymerases are enzymes which are useful in many recombinant DNA techniques such as nucleic acid amplification by the polymerase chain reaction (“PCR"), self- sustained sequence replication (“3SR”), and high temperature DNA sequencing. Thermostable polymerases are particularly useful. Because heat does not destroy the polymerase activity, there is no need to add additional polymerase after every denaturation step.
  • PCR polymerase chain reaction
  • 3SR self- sustained sequence replication
  • Thermostable polymerases are particularly useful. Because heat does not destroy the polymerase activity, there is no need to add additional polymerase after every denaturation step.
  • thermostable polymerases have been found to display a 5' to 3' exonuclease or structure-dependent single-stranded endonuclease ("SDSSE") activity which may limit the amount of product produced or contribute to the plateau phenomenon in the normally exponential accumulation of product.
  • SDSSE structure-dependent single-stranded endonuclease
  • Such 5' to 3' nuclease activity may contribute to an impaired ability to efficiently generate long PCR products greater than or equal to lOkb, particularly for G+C rich targets.
  • the presence of 5' to 3' nuclease activity may contribute to a reduction in desired band intensities and/or generation of spurious or background bands.
  • thermostable DNA polymerase comprising the amino acid sequence set forth in Figure 1 , as well as a purified recombinant thermostable DNA polymerase which exhibits at least about 80% activity at salt concentations of 50 mM and greater.
  • the instant disclosure further teaches a purified recombinant thermostable DNA polymerase which exhibits at least about 70% activity at salt concentrations of 25 mM and greater, and a purified recombinant thermostable DNA polymerase having a processivity of about 30 nucleotides per binding event.
  • the instant disclosure also teaches an isolated nucleic acid that encodes a thermostable DNA polymerase. wherein said nucleic acid consists of the nucleotide sequence set forth in Figure 1 , as well as a recombinant DNA vector that comprises the nucleic acid, and a recombinant host cell transformed with the vector.
  • the instant disclosure also teaches a method of sequencing DNA comprising the step of generating chain terminated fragments from the DNA template to be sequenced with the DNA polymerase in the presence of at least one chain terminating agent and one or more nucleotide triphosphates, and determining the sequence of said DNA from the sizes of said fragments.
  • the instant disclosure also teaches a kit for sequencing DNA comprising the DNA polymerase.
  • FIGURE 1 depicts the amino acid sequence (and DNA sequence encoding therefor) for the FY7 polymerase.
  • FIGURE 2 depicts the DNA sequence of M13mpl8 DNA sequenced using the FY7 polymerase formulated in Mn conditions, as shown by a print out from an ABI model 377 automated fluorescent DNA sequencing apparatus.
  • FIGURE 3 depicts the DNA sequence of M13mpl8 DNA sequenced using the FY7 polymerase formulated in Mg conditions, as shown by a print out from an ABI model 377 automated fluorescent DNA sequencing apparatus.
  • FIGURE 4 depicts the percent of maximum polymerase activity for Thermo SequenaseTM enzyme DNA polymerase versus FY7 DNA polymerase under varying_KCl concentrations.
  • FIGURE 5 depicts the effect of high salt concentrations on DNA sequencing ability in radioactively labeled DNA sequencing reactions using Thermo SequenaseTM enzyme DNA polymerase versus FY7 DNA polymerase.
  • FIGURES 6-10 depict the effect of increasing salt concentration on the performance of Thermo Sequenase. At concentrations as low as 25mM data quality is affected with the read length being decreased from at least 600 bases to about 450 bases. At 50mM salt the read length is further decreased to about 350 bases, 75mM to about 250 bases and at lOOmM the read length is negligible.
  • FIGURES 11-15 depict the effect of increasing salt concentration on the performance of FY7 DNA polymerase. There is no detrimental effect on performance to at least 75mM KCl and only a slight decrease in data quality at lOOmM KCl.
  • FIGURE 16 depicts the processivity measured for Thermo Sequenase DNA polymerase, AmpliTaq FS DNA polymerase, compared with the processivity measured for FY7 DNA polymerase.
  • FIGURE 17 depicts the improved read length obtained when using FY7 polymerase versus Thermo Sequenase DNA polymerase in radioactively labeled sequencing reactions incorporating the dGTP (Guanosine triphosphate) analog dITP (Inosine triphosphate) at 72
  • FIGURES 18-22 show the effect of increasing extension step time on the read length and data quality produced by Thermo Sequenase DNA polymerase in fluorescently labeled terminator DNA sequencing reactions
  • FIGURES 23-27 show the effect of increasing extension step time on the read length and data quality produced by FY7 DNA polymerase in fluorescently labeled terminator DNA sequencing reactions.
  • a series of polymerase mutants were constructed with the aim of obtaining an improved polymerase for DNA sequencing, by reducing the exonuclease activity found in full length Thermus thermophilus and Thermus aquaticus DNA polymerase I enzymes.
  • Six conserved motifs can be identified in the amino-terminal domain of pol I type polymerases, in which the 5' to 3' exonuclease activity has been shown to reside.
  • Tth D18A, Tth T141V, Tth D143N/D145N All of these have the mutation F669Y outside of the exonuclease domain.
  • PCR was employed to introduce an aspartic acid to alanine amino acid change at codon 18 (D18A) of cloned full length F669Y Tth (plasmid pMRlO).
  • Mutagenic Primer 1 (CTGTTCGAACCCAAAGGCCGTGTCCTCCTGGTGGCCGGCCACCAC) spans nucleotides 19-60 of pMRlO including codon 18 and a .RstBI restriction site.
  • Oligonucleotide Primer 2 (GAGGCTGCCGAATTCCAGCCTCTC) spans an EcoRI site of pMRlO. pMRlO was used as template DNA.
  • the PCR product was digested with BstBl and EcoRI and ligated to two fragments of pMRlO: a 5000 bp Kpnll BstBl and a 2057 bp EcoRI / Kpnl, creating plasmid pMR12.
  • Cells of E coli strain DHl ⁇ + were used for primary transformation, and strain M5248 ( ⁇ cI857) was used for protein expression, although any comparable pair of E. coli strains carrying the cl + and cI857 alleles could be utilized.
  • any rec + cl + strain could be induced by chemical agents such as nalidixic acid to produce the polymerase.
  • M5248 containing plasmid pMR12 was grown in one liter of LB medium (1% tryptone. 0.5% yeast extract. 1% NaCl), preferably 2X LB medium, containing 100 mg ml ampicillin at 30°C. When the OD 6 oo reached 1.0, the culture was induced at 42°C for 1.5 hours. The cultures were then cooled to ⁇ 20°C and the cells harvested by centrifugation in a Sorvall RC-3B centrifuge at 5000 rpm at 4°C for 15 to 30 minutes. Harvested cells were stored at -80°C.
  • LB medium 1% tryptone. 0.5% yeast extract. 1% NaCl
  • the cell pellet was resuspended in 25 ml pre-warmed lysis buffer (50 mM Tris-HCI pH 8.0, 10 mM MgCl 2 , 16 mM (NH 4 ) 2 S0 4 , 1 mM ⁇ DTA, 0.1%. preferably 0.2% Tween 20, 0.1%, preferably 0.2% NP40).
  • the lysis buffer contains 300 mM NaCl. Resuspended cells were incubated at 75 - 85°C for 10-20 minutes, sonicated for 1 minute, and cleared by centrifugation.
  • the cleared lysate was passed through a 300 ml column of diethylaminoethyl cellulose (Whatman DE 52) equilibrated in buffer A (50mM Tris-HCl pH 8.0, ImM EDTA. 0.1% Tween 20, 0.1% NP40) containing lOOmM, preferably 300 mM NaCl. Fractions were assayed for polymerase activity, and those demonstrating peak polymerase activity were pooled, diluted to 50 mM NaCl with Buffer A, and loaded onto a heparin sepharose column (20 ml) equilibrated with 50 mM NaCl in buffer A.
  • the polymerase was eluted from the column with a linear salt gradient from 50 mM to 700mM NaCl in buffer A. Fractions were assayed for polymerase activity, and those demonstrating peak activity were pooled and dialyzed against final buffer (20mM Tris-HCl pH8.5, 50 % (v/v) glycerol, O.lmM EDTA, 0.5% Tween 20. 0.5% NP40, ImM DTT, lOOmM KCl). The purified protein is designated FY7. The amino acid sequence (and DNA sequence encoding therefor) are presented in Figure 1. Bacterial Strains
  • E. coli strains DHI ⁇ + [gyrA96, recAl. relAl. endAl, thi-1, hsdR17. supE44, ⁇ "]; M5248 [ ⁇ (bio275. cI857, cIII+, N+, ⁇ (HI))].
  • Plasmid DNA from E. coli DHI ⁇ ⁇ was prepared by SDS alkaline lysis method (Sambrook et al., Molecular Cloning 2 nd Ed. Cold Spring Harbor Press, 1989). Reaction conditions were as follows: 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 0.001% gelatin. luM each primer, 2.5U Taq polymerase, per 100 ⁇ l reaction. Cycling conditions were 94°C 2 minutes, then 35 cycles of 94°C 30s, 55°C 30s, 72°C 3 minutes, followed by 72°C for 7 minutes.
  • Example 1 Formulation of the enzyme in Mn conditions
  • reagent mix A 2.5 ml 1 M HEPPS N-(2-hydroxyethyl) piperazine-N'-(3-propanesulfonic acid), pH 8.0 500 ⁇ l 1 M tartaric acid, pH 8.0 50,000 units FY7 DNA polymerase
  • the volume was made up to 10.000 ⁇ l with deionized H O.
  • the volume was made up to 10.000 ⁇ l with deionized H 2 0.
  • Example 2 Use of the formulation from Example 1
  • Two (2) ⁇ l reagent mix A, 2 ⁇ l reagent mix B, 200 ng M13mpl8 DNA, 5 pmole of primer (Ml 3 - 40 Forward 5'-GTTTTCCCAGTCACGACGTTGTA), and deionized water to a total volume of 20 ⁇ l were mixed together and subjected to 25 cycles of (95 °C 30 seconds, 60 °C 1 minute) in a thermal cycler. After cycling, 4 ⁇ l of a solution which contained 1.5 M sodium acetate. 250 mM EDTA was added. The solution was mixed and 4 volumes (100 ⁇ l) of ethanol added. The DNA was precipitated by incubation on ice for 15-20 minutes followed by centrifugation.
  • Thermoplasma acidophilum inorganic pyrophosphatase 100 ⁇ l 10 mM dITP, 2 mM dATP, 2 mM dTTP.
  • the percent of maximum polymerase activity was measured for Thermo SequenaseTM enzyme DNA polymerase and FY7 DNA polymerase under varyingJ Cl concentrations. The results are depicted in Figure 4. The data indicate that FY7 has a much higher salt optimum as well as broader range of tolerance for salt in the reaction mixture than Thermo SequenaseTM. The salt concentration which gives 50% activity is five-fold higher for FY7 than for Thermo Sequenase.
  • Figures 6-10 show the effect of increasing salt concentration on the performance of Thermo Sequenase. At concentrations as low as 25mM data quality is affected with the read length being decreased from at least 600 bases to about 450 bases. At 50mM salt the read length is further decreased to about 350 bases, 75mM to about 250 bases and at lOOmM the read length is negligible.
  • Figures 11-15 show the effect of increasing salt concentration on the performance of FY7 DNA polymerase. There is no detrimental effect on performance to at least 75mM KCl and only a slight decrease in data quality at lOOmM KCl.
  • Thermo Sequenase DNA polymerase has a processivity of only -4 nucleotides per binding event.
  • AmpliTaq FS DNA polymerase has a processivity of - 15 nucleotides per binding event.
  • FY7 DNA polymerase has a processivity more than seven-fold greater than Thermo Sequenase DNA polymerase and -two-fold greater than AmpliTaq FS DNA polymerase at -30 nucleotides per binding event.
  • Figures 18-22 show the effect of increasing extension step time on the read length and data quality produced by Thermo Sequenase DNA polymerase. This data shows that a minimum of a two minutes extension step is required by Thermo Sequenase in order to achieve a quality read of at least 600 bases. Signal strength generally increases to a maximum at a four minute extension (the time specified in the commercial product utilizing this enzyme and method).
  • Figures 23-27 show the effect of increasing extension step time on the read length and data quality produced by FY7 DNA polymerase. This data shows that a minimum of a 30 second extension step is required by FY7 in order to achieve a quality read of at least 600 bases. Signal strengths plateau at about one minute extension time.
  • the FY7 DNA polymerase can produce data of equivalent quality to Thermo Sequenase in one-quarter to one-half the time of extension reaction.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention se rapporte à une ADN polymérase thermostable, recombinée et purifiée, qui présente au moins 80 % d'activité pour des concentrations de sel supérieures ou égales à 50 mM, et au moins 70 % d'activité pour des concentrations de sel supérieures ou égales à 25 mM, et qui possède une capacité de mise en oeuvre d'environ 30 nucléotides par événement de liaison. L'invention se rapporte à un acide nucléique isolé qui code l'ADN polymérase thermostable, ainsi qu'à un vecteur d'ADN recombiné comportant l'acide nucléique et une cellule hôte recombinée, transformée par ledit vecteur. L'invention se rapporte en outre à une méthode de séquençage d'ADN utilisant ladite ADN polymérase ainsi qu'à une trousse de séquençage d'ADN.
PCT/US1999/013741 1998-06-17 1999-06-17 Fy7 polymerase WO1999065938A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU45757/99A AU768993B2 (en) 1998-06-17 1999-06-17 FY7 polymerase
DE69936919T DE69936919T2 (de) 1998-06-17 1999-06-17 Fy7 polymerase
JP2000554763A JP4349545B2 (ja) 1998-06-17 1999-06-17 Ｆｙ７ポリメラーゼ
CA2330735A CA2330735C (fr) 1998-06-17 1999-06-17 Fy7 polymerase
EP99928766A EP1086209B1 (fr) 1998-06-17 1999-06-17 Fy7 polymerase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8955698P 1998-06-17 1998-06-17
US60/089,556 1998-06-17

Publications (3)

Publication Number Publication Date
WO1999065938A2 true WO1999065938A2 (fr) 1999-12-23
WO1999065938A3 WO1999065938A3 (fr) 2000-04-06
WO1999065938A9 WO1999065938A9 (fr) 2000-06-08

Family

ID=22218300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013741 WO1999065938A2 (fr) 1998-06-17 1999-06-17 Fy7 polymerase

Country Status (9)

Country Link
US (1) US6479267B1 (fr)
EP (1) EP1086209B1 (fr)
JP (1) JP4349545B2 (fr)
CN (1) CN1134538C (fr)
AT (1) ATE371022T1 (fr)
AU (1) AU768993B2 (fr)
CA (1) CA2330735C (fr)
DE (1) DE69936919T2 (fr)
WO (1) WO1999065938A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004632A2 (fr) * 2001-07-06 2003-01-16 Amersham Biosciences Corp Nouvelles adn polymerases comportant des substitutions d'acide amine et homologues de celles-ci
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7476734B2 (en) 2005-12-06 2009-01-13 Helicos Biosciences Corporation Nucleotide analogs
US7482120B2 (en) 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
US7501245B2 (en) 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
US7635562B2 (en) 2004-05-25 2009-12-22 Helicos Biosciences Corporation Methods and devices for nucleic acid sequence determination
US7645596B2 (en) 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
US7981604B2 (en) 2004-02-19 2011-07-19 California Institute Of Technology Methods and kits for analyzing polynucleotide sequences
US9096898B2 (en) 1998-05-01 2015-08-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9657344B2 (en) 2003-11-12 2017-05-23 Fluidigm Corporation Short cycle methods for sequencing polynucleotides

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818395B1 (en) 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
WO2002072892A1 (fr) 2001-03-12 2002-09-19 California Institute Of Technology Procedes et appareil d'analyse de sequences de polynucleotide par extension de base asynchrone
AU2002347981A1 (en) * 2001-11-07 2003-05-19 Applera Corporation Universal nucleotides for nucleic acid analysis
EP1766075B1 (fr) * 2004-06-10 2010-03-17 Amersham Biosciences Corp. Procede d'analyse d'acides nucleiques
US20080305142A1 (en) * 2004-12-11 2008-12-11 Cytogenix, Inc. Cell Free Biosynthesis of High-Quality Nucleic Acid and Uses Thereof
US7397546B2 (en) 2006-03-08 2008-07-08 Helicos Biosciences Corporation Systems and methods for reducing detected intensity non-uniformity in a laser beam
US11525155B2 (en) 2013-03-18 2022-12-13 Qiagen Gmbh Stabilisation of biological samples
GB201721053D0 (en) * 2017-12-15 2018-01-31 Univ I Tromsø - Norges Arktiske Univ DNA polymerases
CN110093410A (zh) * 2019-05-21 2019-08-06 通用生物系统（安徽）有限公司 一种dna测序反应试剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009950A1 (fr) * 1989-12-22 1991-07-11 F. Hoffmann-La Roche Ag Vecteurs d'expression combines et procedes de purification de polymerase d'adn de thermus thermophilus
EP0745676A1 (fr) * 1995-05-31 1996-12-04 Amersham Life Science Inc Polymérase d'ADN thermostable
US5593840A (en) * 1993-01-27 1997-01-14 Oncor, Inc. Amplification of nucleic acid sequences
WO1998001562A1 (fr) * 1996-07-05 1998-01-15 The Mount Sinai School Of Medicine Of The City University Of New York Genes et proteines mutl thermostables et utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618711A (en) 1986-08-22 1997-04-08 Hoffmann-La Roche Inc. Recombinant expression vectors and purification methods for Thermus thermophilus DNA polymerase
US5795762A (en) 1986-08-22 1998-08-18 Roche Molecular Systems, Inc. 5' to 3' exonuclease mutations of thermostable DNA polymerases
JP2531246B2 (ja) * 1988-08-26 1996-09-04 東洋紡績株式会社 耐熱性ｄｎａポリメラ―ゼおよびその製法
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5610066A (en) 1993-12-10 1997-03-11 Amersham Life Science, Inc. Nucleic acid modifying proteins from Pyrococcus furiosus
WO1995030756A1 (fr) 1994-04-18 1995-11-16 United States Biochemical Corporation Phosphatase alcaline thermostable de thermus thermophilus
US5948614A (en) * 1995-09-08 1999-09-07 Life Technologies, Inc. Cloned DNA polymerases from thermotoga maritima and mutants thereof
ATE203056T1 (de) 1995-12-15 2001-07-15 Amersham Life Science Inc Thermostabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus und davon abgeleitete mutierte enzyme mit entfernter exonukleaseaktivität

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009950A1 (fr) * 1989-12-22 1991-07-11 F. Hoffmann-La Roche Ag Vecteurs d'expression combines et procedes de purification de polymerase d'adn de thermus thermophilus
US5593840A (en) * 1993-01-27 1997-01-14 Oncor, Inc. Amplification of nucleic acid sequences
EP0745676A1 (fr) * 1995-05-31 1996-12-04 Amersham Life Science Inc Polymérase d'ADN thermostable
WO1998001562A1 (fr) * 1996-07-05 1998-01-15 The Mount Sinai School Of Medicine Of The City University Of New York Genes et proteines mutl thermostables et utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUTMAN P.D. ET AL: "Conserved sites in the 5'-3' exonuclease domain of Escherichia coli DNA polymerase" NUCLEIC ACIDS RESEARCH, vol. 21, no. 18, 11 September 1993 (1993-09-11), pages 4406-4407, XP000857830 cited in the application *
REEVE M A ET AL: "A NOVEL THERMOSTABLE POLYMERASE FOR DNA SEQUENCING" NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 376, page 796-797 XP000606193 ISSN: 0028-0836 cited in the application *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645596B2 (en) 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9212393B2 (en) 1998-05-01 2015-12-15 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9096898B2 (en) 1998-05-01 2015-08-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US10214774B2 (en) 1998-05-01 2019-02-26 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US10208341B2 (en) 1998-05-01 2019-02-19 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9957561B2 (en) 1998-05-01 2018-05-01 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9458500B2 (en) 1998-05-01 2016-10-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9725764B2 (en) 1998-05-01 2017-08-08 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7501245B2 (en) 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
WO2003004632A2 (fr) * 2001-07-06 2003-01-16 Amersham Biosciences Corp Nouvelles adn polymerases comportant des substitutions d'acide amine et homologues de celles-ci
US6875573B2 (en) 2001-07-06 2005-04-05 Amersham Biosciences Corp DNA polymerases having amino acid substitutions and homologs thereof
WO2003004632A3 (fr) * 2001-07-06 2003-10-16 Amersham Biosciences Corp Nouvelles adn polymerases comportant des substitutions d'acide amine et homologues de celles-ci
US9657344B2 (en) 2003-11-12 2017-05-23 Fluidigm Corporation Short cycle methods for sequencing polynucleotides
US7981604B2 (en) 2004-02-19 2011-07-19 California Institute Of Technology Methods and kits for analyzing polynucleotide sequences
US7635562B2 (en) 2004-05-25 2009-12-22 Helicos Biosciences Corporation Methods and devices for nucleic acid sequence determination
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7482120B2 (en) 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
US9868978B2 (en) 2005-08-26 2018-01-16 Fluidigm Corporation Single molecule sequencing of captured nucleic acids
US7476734B2 (en) 2005-12-06 2009-01-13 Helicos Biosciences Corporation Nucleotide analogs

Also Published As

Publication number Publication date
JP2002517997A (ja) 2002-06-25
WO1999065938A3 (fr) 2000-04-06
CN1313893A (zh) 2001-09-19
AU768993B2 (en) 2004-01-15
DE69936919D1 (en) 2007-10-04
WO1999065938A9 (fr) 2000-06-08
JP4349545B2 (ja) 2009-10-21
CA2330735C (fr) 2010-05-11
CA2330735A1 (fr) 1999-12-23
AU4575799A (en) 2000-01-05
DE69936919T2 (de) 2008-05-15
US6479267B1 (en) 2002-11-12
EP1086209B1 (fr) 2007-08-22
CN1134538C (zh) 2004-01-14
ATE371022T1 (de) 2007-09-15
EP1086209A2 (fr) 2001-03-28

Similar Documents

Publication Publication Date Title
EP1086209B1 (fr) Fy7 polymerase
JP7640606B2 (ja) 増大した鋳型識別活性を有するｄｎａポリメラーゼ突然変異体
Takagi et al. Characterization of DNA polymerase from Pyrococcus sp. strain KOD1 and its application to PCR
US9102924B2 (en) DNA polymerases and related methods
CA2742593C (fr) Adn polymerases chimeriques
US20060252083A1 (en) Methods of synthesizing polynucleotides using thermostable enzymes
CA2888148C (fr) Adn polymerases a activite amelioree
CA2831180C (fr) Adn polymerases avec une activite amelioree
Hamilton et al. DNA polymerases as engines for biotechnology
JP2003511044A (ja) Ｄｎａの増幅、合成及び突然変異誘発のための組成物
KR101622442B1 (ko) ３’―미스매치 구별이 증가된 ｄｎａ 중합효소
US7078170B2 (en) Reaction mixtures for target amplification of nucleic acid with mutant RNA polymerase
WO2006081463A2 (fr) Adn polymerases de thermococcus zilligii et leurs variants
JP7180944B1 (ja) 改変型ｄｎａポリメラーゼ
EP1212430A1 (fr) Variants de nuclease et leur utilisation dans des bioanalyses de genotypage
WO2007035439A1 (fr) Clonage et purification de la ligase d'adn du thermococcus sp. (souche 9°n-7)
EP2582801B1 (fr) Polymerases adn avec une distinction ameliorées des mésappariements 3' de paires de bases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809812.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-9, DESCRIPTION, REPLACED BY NEW PAGES 1-9; PAGES 10-11, CLAIMS, REPLACED BY NEW PAGES 10-11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2330735

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2000 554763

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999928766

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 45757/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999928766

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 45757/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999928766

Country of ref document: EP